Anna Berekmeri
Overview
Explore the profile of Anna Berekmeri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wittmann M, Smith I, Brown S, Berekmeri A, Vargas-Palacios A, Sunderland L, et al.
Health Technol Assess
. 2024 Oct;
28(59):1-123.
PMID: 39364555
Background: Hand eczema is common and a cause of morbidity and occupational disability. When education, irritant/contact allergen avoidance, moisturisation and topical corticosteroids are insufficient to control chronic hand eczema, ultraviolet...
2.
Berekmeri A, Macleod T, Hyde I, Ojak G, Mann C, Kramer D, et al.
J Eur Acad Dermatol Venereol
. 2024 Aug;
PMID: 39157924
Background: Eczema and psoriasis are common diseases. Despite both showing active epidermal contribution to the inflammatory process, their molecular aetiology and pathological mechanisms are different. Objective: Further molecular insight into...
3.
Macleod T, Berekmeri A, Bridgewood C, Stacey M, McGonagle D, Wittmann M
Front Immunol
. 2022 Jan;
12:808012.
PMID: 35003136
The skin barrier would not function without IL-1 family members, but their physiological role in the immunological aspects of skin barrier function are often overlooked. This review summarises the role...
4.
De Marco G, Berekmeri A, Coates L, Dubash S, Emmel J, Gladman D, et al.
Rheumatol Adv Pract
. 2021 Feb;
4(2):rkaa032.
PMID: 33542971
Background: Psoriatic disease (PsD) is a complex systemic disorder with cutaneous and musculoskeletal manifestations. Current evidence on pharmacological interventions, effective across the spectrum of clinical manifestations of early, systemic treatment-naïve...
5.
Berekmeri A, Tiganescu A, Alase A, Vital E, Stacey M, Wittmann M
Front Immunol
. 2019 Sep;
10:1931.
PMID: 31497014
The traditional diagnostic gold standard for inflammatory skin lesions of unclear etiology is dermato-histopathology. As this approach requires an invasive skin biopsy, biopsy processing and analysis by specialized histologists, it...
6.
Shalbaf M, Alase A, Berekmeri A, Md Yusof M, Pistolic J, Goodfield M, et al.
Lupus Sci Med
. 2019 Aug;
6(1):e000328.
PMID: 31413850
Objective: When faced with clinical symptoms of scarring alopecia-the standard diagnostic pathway involves a scalp biopsy which is an invasive and expensive procedure. This project aimed to assess if plucked...
7.
Berekmeri A, Mahmood F, Wittmann M, Helliwell P
Expert Rev Clin Immunol
. 2018 Aug;
14(9):719-730.
PMID: 30118353
Psoriasis and psoriatic arthritis (PsA) are inflammatory immune-mediated conditions which can cause considerable disability and reduced quality of life. Management can be complex as clinical heterogeneity may lead to different...
8.
Berekmeri A, Latzko A, Alase A, Macleod T, Ainscough J, Laws P, et al.
J Allergy Clin Immunol
. 2018 May;
142(3):988-991.e4.
PMID: 29782895
No abstract available.
9.
Bridgewood C, Fearnley G, Berekmeri A, Laws P, Macleod T, Ponnambalam S, et al.
Front Immunol
. 2018 Mar;
9:200.
PMID: 29535706
The IL-1 family member cytokine IL-36γ is recognised as key mediator in the immunopathology of psoriasis, hallmarks of which involve the activation of both resident and infiltrating inflammatory myeloid cells...